Erik Storkebaum

Has grant

Scientific Director

Radboud Universiteit Donders Institute for Brain Cognition and Behaviour
Country flagNetherlands

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Optimisation of a gene therapy for Hereditary Motor and Sensory Neuropathy (HMSN) type 2D

Open Date: 2026-07-01

Close Date: 2030-06-01

Grant: Open

AAV9-tRNA-Gly: Towards a first effective therapy for Charcot-Marie-Tooth peripheral neuropathy

Open Date: 2025-09-01

Close Date: 2027-02-01

Grant: Open

tRNA for CMT

Open Date: 2025-09-01

Close Date: 2027-08-01

Grant: Open

AAV-mediated gene transfer of tRNA: a revolutionary approach to treat Charcot-Marie-Tooth disease

Open Date: 2025-09-01

Close Date: 2027-08-01

Grant: Open

Dissecting the role of the skeletal muscle in TDP-43-ALS

Open Date: 2025-04-01

Close Date: 2029-03-01

Articles (8)

Year:

2026

Axonal and synaptic degeneration are key hallmarks of neurodegenerative diseases, but the underlying molecular mechanisms are incompletely understood. Here, we performed an unbiased forward genetic mosaic screen to identify genes required for maintenance of adult motor axons and neuromuscular junctions (NMJs) in the Drosophila leg. We identified 49 mutations in 30 genes, including mutations in 8 genes resulting in adult-onset progressive degeneration. We found that loss of pebbled ( peb ) function results in adult-onset motor axonal and NMJ degeneration, and age-dependent motor deficits. Peb is the Drosophila RREB1 ortholog, a C 2 H 2 zinc-finger transcription factor that negatively regulates transcription of RAS/MAPK pathway target genes. Loss of peb function resulted in excessive RAS/MAPK pathway activation, and loss of function of other negative regulators of the RAS/MAPK pathway also induced adult-onset progressive NMJ degeneration and motor deficits. Importantly, treatment of adult flies with the MEK1/2 inhibitor mirdametinib induced a dosage-dependent rescue of peb mutant motor neurodegenerative phenotypes. Thus, RAS/MAPK pathway overactivation results in adult-onset progressive neurodegeneration, which can be prevented by RAS/MAPK pathway inhibition.

Year:

2025

Amyotrophic lateral sclerosis (ALS) leads to death within 2–5 yr. Currently, available drugs only slightly prolong survival. We present novel insights into the pathophysiology of Superoxide Dismutase 1 (SOD1)- and in particular Fused In Sarcoma (FUS)-ALS by revealing a supposedly central role of glycolic acid (GA) and D-lactic acid (DL)—both putative products of the Parkinson’s disease associated glyoxylase DJ-1. Combined, not single, treatment with GA/DL restored axonal organelle phenotypes of mitochondria and lysosomes in FUS- and SOD1-ALS patient-derived motoneurons (MNs). This was not only accompanied by restoration of mitochondrial membrane potential but even dependent on it. Despite presenting an axonal transport deficiency as well, TDP43 patient-derived MNs did not share mitochondrial depolarization and did not respond to GA/DL treatment. GA and DL also restored cytoplasmic mislocalization of FUS and FUS recruitment to DNA damage sites, recently reported being upstream of the mitochondrial phenotypes in FUS-ALS. Whereas these data point towards the necessity of individualized (gene-) specific therapy stratification, it also suggests common therapeutic targets across different neurodegenerative diseases characterized by mitochondrial depolarization.

Year:

2024

Post-transcriptional modification of RNA regulates gene expression at multiple levels. ALKBH8 is a tRNA-modifying enzyme that methylates wobble uridines in a subset of tRNAs to modulate translation. Through methylation of tRNA-selenocysteine, ALKBH8 promotes selenoprotein synthesis and regulates redox homeostasis. Pathogenic variants in ALKBH8 have been linked to intellectual disability disorders in the human population, but the role of ALKBH8 in the nervous system is unknown. Through in vivo studies in Drosophila , we show that ALKBH8 controls oxidative stress in the brain to restrain synaptic growth and support learning and memory. ALKBH8 null animals lack wobble uridine methylation and exhibit reduced protein synthesis in the nervous system, including a specific decrease in selenoprotein levels. Either loss of ALKBH8 or independent disruption of selenoprotein synthesis results in ectopic synapse formation. Genetic expression of antioxidant enzymes fully suppresses synaptic overgrowth in ALKBH8 null animals, confirming oxidative stress as the underlying cause of dysregulation. ALKBH8 null animals also exhibit associative memory impairments that are reversed by pharmacological antioxidant treatment. Together, these findings demonstrate the critical role of tRNA wobble uridine modification in redox homeostasis in the developing nervous system and reveal antioxidants as a potential therapy for ALKBH8-associated intellectual disability.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (13)

Jared Sterneckert

Professor Dr. at Technische Universität Dresden

Technische Universität Dresden

GERMANY
View details

Dragony Fu

Professor

University of Rochester

UNITED STATES
View details

Stephan Zuchner

University of Miami Miller School of Medicine

UNITED STATES
View details

Deniz Yilmazer-Hanke

Professor, Section Head

Universität Ulm

GERMANY
View details

Patrik Verstreken

Group Leader, Director and Professor

KU Leuven

BELGIUM
View details

Stéphanie Millecamps

Associate Professor

Centre National de la Recherche Scientifique (CNRS)

FRANCE
View details

Kimberly Bonger

PI Chemical Biology & Immunology

Leiden University

NETHERLANDS
View details

Alberto Catanese

Director

Université Paris Descartes

FRANCE
View details

Annette Schenck

full Prof

Radboud University Medical Center

NETHERLANDS
View details

Christian Gilissen

Professor of Genome Bioinformatics

Universitair Medisch Centrum Utrecht

NETHERLANDS
View details

Jan Veldink

Professor of Neurology and Neurogenetics

University Medical Center Utrecht, Utrecht University

NETHERLANDS
View details

Luc Dupuis

University of Strasbourg

FRANCE
View details

Michiel Vermeulen

Senior group leader

Radboud Universiteit Nijmegen

NETHERLANDS
View details